Showing results (91-100 of 1,059) with videos related to
Sort By:
Pageof 106
Alzheimer'S & Dementia (New York, N. Y.)|July 1, 2021
Building clinically relevant outcomes across the Alzheimer's disease spectrumDorene M Rentz, Alette M Wessels, Ananth V Annapragada, et al.Alzheimer'S & Dementia (New York, N. Y.)|December 7, 2018
Cerebrospinal fluid neurogranin/β-site APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's diseaseBjørn-Eivind Kirsebom, Kaja Nordengen, Per Selnes, et al.Alzheimer'S & Dementia (New York, N. Y.)|March 22, 2018
Effect of donepezil on transcranial magnetic stimulation parameters in Alzheimer's diseaseYun Tae Hwang, Lorenzo Rocchi, Paul Hammond, et al.Alzheimer'S & Dementia (New York, N. Y.)|December 19, 2018
Opioid use and the presence of Alzheimer's disease and related dementias among elderly Medicare beneficiaries diagnosed with chronic pain conditionsChan Shen, Xiaohui Zhao, Nilanjana Dwibedi, et al.Alzheimer'S & Dementia (New York, N. Y.)|December 25, 2018
Alzheimer's disease in Down syndrome: An overlooked population for prevention trialsAndré Strydom, Antonia Coppus, Rafael Blesa, et al.Alzheimer'S & Dementia (New York, N. Y.)|June 9, 2022
Integrated Alzheimer's Disease Rating Scale: Clinically meaningful change estimatesAlette M Wessels, Dorene M Rentz, Michael Case, et al.Alzheimer'S & Dementia (New York, N. Y.)|May 20, 2022
Lateralized ante mortem and post mortem pathology in a case of Lewy body disease with corticobasal syndromeDavid G Coughlin, H Branch Coslett, Claire Peterson, et al.Alzheimer'S & Dementia (New York, N. Y.)|July 1, 2022
Cost-effectiveness of dementia training for caregivers in caregiver-patient dyads: A randomized controlled studyElizabeth G Birkenhäger-Gillesse, Wilco P Achterberg, Sarah I M Janus, et al.Alzheimer'S & Dementia (New York, N. Y.)|June 7, 2021
Intepirdine as adjunctive therapy to donepezil for mild-to-moderate Alzheimer's disease: A randomized, placebo-controlled, phase 3 clinical trial (MINDSET)Frederick M Lang, Yi Mo, Marwan Sabbagh, et al.Alzheimer'S & Dementia (New York, N. Y.)|June 7, 2021
Alzheimer's disease drug development pipeline: 2021Jeffrey Cummings, Garam Lee, Kate Zhong, et al.Pageof 106